XTL Biopharmaceuticals Ltd. (XTLB)

XTL Biopharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	1.4	2.09	2.97	3.63	4.46
Short-Term Investments	0.61	1.63	3.16	2.41	2.27
Cash & Cash Equivalents	2.01	3.72	6.13	6.04	6.73
Cash Growth	-46.09%	-39.27%	1.41%	-10.20%	-17.16%
Other Current Assets	0.04	0.09	0.11	0.08	0.1
Total Current Assets	2.05	3.81	6.24	6.12	6.83
Property, Plant & Equipment	0	0	0	0	0
Goodwill and Intangibles	0.38	0.38	0.38	0.38	0.38
Total Long-Term Assets	0.38	0.38	0.38	0.38	0.38
Total Assets	2.43	4.19	6.62	6.5	7.21
Accounts Payable	0.21	0.19	0.23	0.25	0.23
Total Liabilities	0.21	0.19	1.29	2.89	0.7
Retained Earnings	-158.25	-156.47	-155.13	-155.61	-152.7
Shareholders' Equity	2.22	4	5.33	3.61	6.52
Net Cash / Debt	2.01	3.72	6.13	6.04	6.73
Net Cash / Debt Growth	-46.09%	-39.27%	1.41%	-10.20%	-17.16%
Net Cash Per Share	0.00	0.01	0.01	0.01	0.01
Book Value Per Share	0.41	0.73	1.00	0.70	1.27

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).